Molnupiravir and Drug Development at Emory | Emory University
Emory University has discovered and advanced the development of some of the world’s most important and valuable antiviral drugs, successfully moving treatments from the lab to the bedside.
As one of the nation’s leading research universities, a key mission for Emory is to improve the lives and give hope to all those we serve in all facets of our work. The criteria by which we measure our success include, but are not limited to, lives saved, partnerships forged, solutions to real-world problems, as well as scientific discoveries and foundations developed that will improve health, well-being. being and the safety of individuals around the world. for generations to come.
Drug Innovation Ventures in Emory (DRIVE), LLC, a nonprofit biotech company 100% owned by Emory University, invented EIDD-2801, which is now Molnupiravir. Drugs targets viral polymerase, an enzyme needed by the virus to reproduce. The oral antiviral is designed to work by introducing errors into the genetic code of the virus.
Molnupiravir is currently being developed by Merck & Co. Inc. in collaboration with Ridgeback Biotherapeutics, which licensed the drug to DRIVE in 2020.. This could be the first oral antiviral drug to treat COVID-19.
October 11, Merck and Ridgeback announcement Submission of an EUA application to the FDA for Molnupiravir.